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January 7, 2014 up to 65% and showed an encouraging safety and tolerability profile in 4 randomized, placebo-controlled, phase 2 clinical trials in >1300 hypercholesterolemic patients. 4, 5, 7, 10 To date, the only report evaluating an anti-PCSK9 inhibitor for >12 weeks involved 8 patients with homozygous familial hypercholesterolemia. 11 No previous reports have comprehensively evaluated the efficacy and safety of any PCSK9 inhibitor through 1 year or in a large and diverse patient population.
To provide such data on evolocumab, patients completing any of the 4 phase 2 trials could participate in the Open-Label Study of Long-term Evaluation Against LDL-C (OSLER), a global, multicenter, randomized, controlled, open-label extension trial in which investigators could adjust background standard-of-care (SOC) therapy, including medications, after 12 weeks. The present analysis reports the efficacy and safety results for hypercholesterolemic patients treated in OSLER for 1 year.
Methods

Study Design and Patients
OSLER was a global study conducted at 156 study centers that participated in 1 4, 5, 7, 10, 12 Patients completing any evolocumab phase 2 parent study could enroll in OSLER provided that they did not experience a treatment-related serious adverse event (AE) that led to discontinuation of investigational product in the phase 2 parent study or were anticipated to require unblinded lipid measurements and/or adjustment of background lipid-regulating therapy during the first 12 weeks of OSLER participation. An independent ethics committee or institutional review board approved the protocol, and all patients provided written informed consent before enrollment in the extension study.
Schedule of Events
Randomization of eligible patients occurred ideally at or within 3 days of the phase 2 parent end-of-study visit. Patients were randomized in a 2:1 fashion to 1 of 2 treatment groups, regardless of their treatment assignments during the phase 2 parent study: either evolocumab 420 mg SC every 4 weeks plus SOC (evolocumab+SOC; n=736) or SOC alone (n=368). The SOC-only group served as the control arm ( Figure 1 ). SOC was based on local guidelines for the treatment of hypercholesterolemia. After the first 12 weeks, central laboratory lipid results were unblinded, and investigators could adjust SOC therapies in both arms. Downtitration of statins continued from a phase 2 parent study was prohibited if the decision was based on unblinded LDL-C values obtained after week 12.
Study visits occurred every 4 weeks for patients randomized to evolocumab+SOC. After their week 4 visits, patients randomized to SOC returned to the study center only for quarterly visits thereafter (weeks 12, 24, 36, 48, and 52); all other interval visits (every 4 weeks) were conducted over the phone. Sites collected blood samples at week 4 and at the quarterly visits.
Efficacy and Safety End Points
The primary efficacy objective was to characterize the effects of longer-term administration of evolocumab as assessed by LDL-C, non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein (Apo) B, ratio of total cholesterol to HDL-C, and ApoB/ApoA1 ratio in patients with hypercholesterolemia. The primary safety objective was to characterize the safety and tolerability of longerterm administration of evolocumab. Safety end points included the incidence of AEs, serious AEs, and AEs leading to discontinuation of investigational product. Other safety end points included the incidence of creatine kinase and liver function test abnormalities and the incidence and percentage of patients who developed anti-evolocumab antibodies (binding or neutralizing). Clinical events were adjudicated by an independent Clinical Events Committee and included cardiovascular and muscle-related events (see the Appendix in the onlineonly Data Supplement). An independent Data Monitoring Committee regularly reviewed data from this and other ongoing evolocumab studies, prepared by an external biostatistical group.
Laboratory Methods
Plasma lipids, ApoA1, ApoB, and lipoprotein(a) were measured after a fast of ≥9 hours on day 1 of open-label treatment (end-of-study visit for phase 2 parent study), at week 4, and every 12 weeks (weeks 12, 24, 36, 48, 52) for 1 year. LDL-C values with preparative ultracentrifugation 13 were obtained on day 1 and at 12-week intervals. All LDL-C values reported are based on the preparative ultracentrifugation method except those at week 4. Safety laboratory tests were performed by Covance Laboratories (Indianapolis, IN, or Geneva, Switzerland) and included serum chemistry, hematology, urinalysis, high-sensitivity C-reactive protein, and hemoglobin A 1c .
Analyses of serum lipids [total cholesterol, HDL-C, LDL-C, non-HDL-C, triglycerides, ApoB, ApoA1, and lipoprotein(a)] were performed by a central laboratory, Medpace Reference Laboratories (Cincinnati, OH, and Leuven, Belgium). LDL-C and very-low-density lipoprotein cholesterol were measured after preparative ultracentrifugation (β quantification).
14 LDL-C was also calculated with the Friedewald formula. 15 Binding and neutralizing anti-evolocumab antibodies were assayed as reported previously. 3 Additional details of laboratory methods are included in the Appendix in the online-only Data Supplement.
Statistical Analysis
For all end points, data were summarized for patients by the randomized treatment group. Patients were further categorized according to whether they were randomized to evolocumab in the phase 2 parent studies. AEs were coded with the use of the Medical Dictionary for Regulatory Activities, version 16.0. Summary statistics for continuous variables included the number of patients, mean, median, standard deviation or standard error, 25th percentile, 75th percentile, minimum, and maximum. For categorical variables, the frequency and percentage were presented. All data analyses were based on observed values.
For continuous analyses, a 1-sample t test or Wilcoxon signed rank test was used for the comparisons with parent baseline and a 2-sample t test or Wilcoxon rank sum test was used for between-group comparisons. For categorical analyses, a χ 2 test was used to compare between treatment groups. All statistical tests were based on a 2-sided significance level of 0.05 without multiplicity adjustment. All statistical analyses were performed with SAS version 9.3.
Results
Patients
A total of 1104 patients enrolled in OSLER (81.2% of those randomized and dosed in phase 2 parent studies); most (88.0%) enrolled within 3 days of their last phase 2 parent study visits. Of the 1104 patients, 736 were randomized to receive evolocumab 420 mg every 4 weeks subcutaneously+SOC and 368 were randomized to receive SOC only for 52 weeks (Figure 1 (Table 1 and Table I in the online-only Data Supplement). A total of 691 patients (62.6%) were on statin therapy at baseline, and of those 691 patients, 295 (42.7%) received intensive statin therapy (defined as daily doses of atorvastatin ≥40 mg, rosuvastatin ≥20 mg, simvastatin 80 mg, or any statin plus ezetimibe). The proportion of patients who received statin therapy at baseline was higher in the evolocumab+SOC group (64.9%) compared with the SOC group (57.9%).
Only 4 of 736 patients (<1%) receiving evolocumab either discontinued a statin or switched from an intensive to a nonintensive statin regimen, and only 2 of 368 patients (<1%) in the SOC-only group discontinued statin use. A total of 20 patients (2.7%) in the evolocumab+SOC group and 33 patients (9.0%) in the SOC-only group initiated statin therapy during OSLER. Another 25 patients (6.8%) in the SOC group and 14 patients (1.9%) in the evolocumab+SOC group started taking nonstatin lipid-lowering therapies during OSLER, and 5 patients (1.4%) in the SOC group and 6 patients (0.8%) in the evolocumab+SOC group continued taking nonstatin lipid-lowering therapies during OSLER.
Efficacy Outcomes
Patients not taking evolocumab in the phase 2 parent study had large initial LDL-C reductions determined at 12 weeks after starting evolocumab treatment in OSLER (51.8% [SE, 1.6%] reduction from the parent study baseline; P<0.0001 versus baseline), with reductions maintained over the 52-week study period (52.3% [SE, 1.8%] at week 52; P<0.0001 versus baseline; Figure 2 and Table II Percentage changes from the phase 2 parent study baseline in other lipid parameters, including ApoB, lipoprotein(a), and triglycerides, are shown in Figure 3 and Table III in evolocumab. Median triglyceride levels fell slightly in the evolocumab+SOC groups over 52 weeks ( Figure 3 ). Evolocumab+SOC patients reached ultracentrifugation LDL-C levels of <2.6 mmol/L (100 mg/dL) or <1.8 mmol/L (70 mg/dL) more frequently than patients on SOC alone. Among the patients who had at least 1 ultracentrifugation LDL-C post baseline value during OSLER, LDL-C <2.6 mmol/L (100 mg/dL) was achieved at least at 1 visit by 96.0% of patients treated with evolocumab+SOC but only 32.4% of patients in the SOC group (P<0.0001; Table 2 ). Among the patients who had ultracentrifugation LDL-C values at all OSLER visits, LDL-C <2.6 mmol/L (100 mg/ dL) was achieved at every visit by 72.1% of patients treated with evolocumab+SOC but only 3.3% of patients in the SOC group (P<0.0001) over 52 weeks. Similarly, LDL-C <1.8 mmol/L (70 mg/dL) was achieved at least at 1 visit by 82.8% of patients treated with evolocumab+SOC but only 3.6% of patients in the SOC group (P<0.0001). Among the patients who had ultracentrifugation LDL-C values at all OSLER visits, LDL-C <1.8 mmol/L (70 mg/dL) was achieved at every visit by 37.8% of patients treated with evolocumab+SOC and no patients in the SOC group (P<0.0001).
Achievement of ultracentrifugation LDL-C levels of <1.3 mmol/L (50 mg/dL) or <0.65 mmol/L (25 mg/dL) at any OSLER visit occurred in 55.6% and 13.3% of evolocumab+SOC patients, respectively. In contrast, only 2 patients (0.5%) in the SOC group reached LDL-C <1. 
Safety and Tolerability
Adverse events occurred in 269 patients (73.1%) in the SOC group and 599 patients (81.4%) in the evolocumab+SOC group (Table 3 ). The 5 most commonly reported AEs in the 2 groups were nasopharyngitis, upper respiratory tract infections, influenza, arthralgia, and back pain. Investigators considered AEs as possibly related to evolocumab in 5.6% of all AEs. Six patients (1.6%) in the SOC group and 13 patients (1.8%) in the evolocumab+SOC group had alanine aminotransferase or aspartate aminotransferase values >3 times the upper limit of normal. One patient (0.3%) in the SOC group and 4 patients (0.5%) in the evolocumab+SOC group experienced an elevation in alanine aminotransferase or aspartate aminotransferase >5 times the upper limit of normal. Serious AEs occurred in 23 SOC patients (6.3%) and 52 patients (7.1%) in the evolocumab+SOC group. No particular serious AEs affected ≥2% of patients in either group or was considered by investigators to be possibly related to evolocumab. Twenty-seven patients (3.7%) had AEs that led to the discontinuation of evolocumab, with low frequencies of specific events (Table IV in the onlineonly Data Supplement). Injection-site reactions were reported in 38 patients (5.2%) in the evolocumab+SOC group and led to discontinuation of evolocumab in only 1 patient. No patient in the SOC group received evolocumab or placebo injections during the study. No neutralizing antibodies to evolocumab were detected in OSLER. Low-titer binding antibodies were detected Lipid parameters at the parent study baseline ApoA1 indicates apolipoprotein A1; ApoB, apolipoprotein B; HDL-C, highdensity lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Lp(a): lipoprotein(a); PCSK9. proprotein convertase subtilisin kexin 9 Q1, 25th percentile; Q3, 75th percentile; SD, standard deviation; SOC, standard of care; and VLDL-C, very low-density lipoprotein cholesterol.
*Based on the presence of angina, myocardial infarction, coronary artery bypass graft, or percutaneous coronary intervention.
†Based on presence of coronary heart disease in a first-degree relative male ≤55 years of age or female relative ≤65 year of age. ‡Defined as having 3 or more of the following factors: elevated waist circumference, triglycerides ≥150 mg/dL, low HDL-C (<40 mg/dL in men and <50 mg/dL in women), systolic blood pressure ≥130 mm Hg or diastolic blood pressure ≥85 mm Hg, or hypertension. at week 4 of OSLER in 2 patients in the SOC group who had received evolocumab in the phase 2 parent study; results at subsequent time points were negative for binding antibodies. A total of 411 patients (99.5% of whom were receiving evolocumab) achieved LDL-C <1.3 mmol/L (50 mg/dL), and 98 patients (all of whom were receiving evolocumab) achieved LDL-C <0.65 mmol/L (25 mg/dL), whereas 682 patients (47.4% of whom were receiving evolocumab) had LDL-C levels ≥1.3 mmol/L (50 mg/dL). Overall AEs, serious AEs, elevations in creatine kinase, and elevations in aminotransferases were not appreciably greater in those who achieved low LDL-C (Table 4 and Table V in the online-only Data Supplement). Headaches, dizziness, insomnia, and back pain tended to occur with greater frequency in those with lower LDL-C. A total of 2.2% of patients in the SOC group and 1.2% patients in the evolocumab+SOC group experienced an adjudicated cardiovascular clinical event (Table 5) . Three deaths were reported during the 52-week study. Two patients died in the SOC group: a 53-year-old man who did not receive evolocumab in the phase 2 parent study died of unknown causes at 7.3 months, and a 40-year-old woman who received evolocumab in a parent study died of a pulmonary embolism at 9.8 months. A 45-year-old man in the evolocumab+SOC group who also received evolocumab in the phase 2 parent study and was known to have significant coronary artery disease and a ventricular aneurysm was found to be deceased during month 5 of OSLER.
Discussion
As the first large longer-term evaluation of a PCSK9 inhibitor, findings from the OSLER trial extend the understanding of a novel therapy and provide insight into the efficacy, safety, and tolerability of evolocumab treatment in hypercholesterolemic patients. Evolocumab reduced LDL-C on average by ≈50% beyond the reduction achieved with optimal SOC in various hypercholesterolemic patient populations. The reductions in lipid levels achieved after 12 weeks were stable over the course of the study without evidence of attenuation. Conversely, discontinuation of evolocumab led to a fairly rapid return to baseline levels, although importantly, without a rebound phenomenon. OSLER enrolled a heterogeneous group of participants recruited from phase 2 studies of hypercholesterolemic patients on a statin, 4 not on a statin, 5 intolerant to statins, 10 and with heterozygous familial hypercholesterolemia. 7 This heterogeneity in the population provides a broad view of how a novel therapy may affect a spectrum of patients. For example, we found that 72.1% of evolocumab-treated patients reached LDL-C levels <2.6 mmol/L (100 mg/dL) at all lipid measurements over 52 weeks compared with 3.3% of the SOC group patients, even though SOC patients could have their therapy adjusted after 12 weeks into the study.
As healthcare quality assessments shift toward measured outcomes, the predictability of achieving lipid treatment targets as demonstrated in OSLER will likely take on additional importance. Anti-PCSK9 antibodies, if deployed strategically, may lead to greater numbers within a treated population reaching and maintaining stable goals for LDL-C and other lipoproteins. Challenging patients such as those who fail to reach current lipid goals despite maximum doses of highly effective statin agents or those with well-documented statin intolerance are thus logical populations for treatment with PCSK9 inhibitors.
More broadly, the emergence of anti-PCSK9 therapies may provide a means to help answer the long-debated clinical question of how low to reduce LDL-C in patients at risk. Several lines of evidence suggest that further clinical benefits could accrue from lowering LDL-C to levels below those currently advocated. This evidence includes Mendelian randomization analyses showing that genetic variations that produce very low levels of LDL-C confer high levels of protection against atherosclerotic complications without known offsetting morbidity or mortality. 16, 17 Observations from statin clinical trials provide another compelling argument for aggressive treatment. In these trials, cohorts with the lowest LDL-C levels consistently experienced the fewest 18, 19 OSLER demonstrated that the vast majority of patients treated with evolocumab can achieve LDL-C levels significantly below current guidelines. The high percentage of OSLER patients with LDL-C <1.3 mmol/L (50 mg/dL), especially those with coadministered statin therapy, suggests that future cardiovascular outcomes trials with evolocumab may be useful to explore the benefit of LDL-C reductions beyond current targets. These studies may also help to define whether clinical gains accrue from the further therapeutic upregulation of LDL receptors, a mechanism of action that PCSK9 inhibition shares with statin therapy.
In terms of tolerability, the high participation rate (81%) from the phase 2 parent evolocumab studies reflects good tolerance of the parenteral therapy, as reported in the shortterm studies. 4, 5, 7, 10 Moreover, the low rate of patients who discontinued evolocumab due to AEs (3.7%) also indicates excellent ongoing acceptance of the therapy. Overall, AEs were approximately balanced between the evolocumab+SOC and SOC groups over a year of treatment despite more frequent on-site contact in the evolocumab+SOC group. Injection-site reactions occurred in 5.2% of patients in the evolocumab+SOC group. Side effects of particular concern such as liver function test abnormalities, muscle symptoms, or laboratory abnormalities occurred no more frequently in evolocumab-treated patients than in those treated with SOC.
In addition, the absence of neutralizing antibodies and the rarity of binding antibodies in OSLER provide reassurance about the long-term immunogenicity of evolocumab and are consistent with observations in the short-term evolocumab studies. These findings are important because even small untoward off-target effects of LDL-C-lowering therapy may mask or outweigh the antiatherosclerotic benefits of a lipidlowering treatment. This phenomenon may have affected outcomes in trials of previously studied agents that have positively affected lipid profiles but have led to negative or neutral clinical results. [20] [21] [22] [23] OSLER also provides information about the safety of treating patients to low and very low levels of LDL-C over 1 year. Overall AE rates, serious AE rates, and elevations in creatine kinase and aminotransferases were not appreciably greater in those who achieved low LDL-C. These data suggest that evolocumab may offer significant gains in additional LDL-C lowering without incurring the increased likelihood of untoward laboratory effects, as seen during dose escalation of statins.
24-26 OSLER patients who reached low and very low LDL-C levels reported slightly higher rates of headache, dizziness, insomnia, and back pain. This slightly higher reported rate of minor, subjective symptoms requires cautious interpretation because it may have resulted from an asymmetry in the protocol design, which required a greater number of face-toface interactions with site personnel for patients treated with injection therapy. Hemorrhagic stroke, a reported cause of concern related to low levels of LDL-C, was not observed during OSLER, and other forms of neurological dysfunction such as amnesia and memory/mental impairment were reported uncommonly (in ≤1% of patients in any group). Safety observations related to the achievement of low LDL-C levels warrant continued investigation, particularly in studies in which lipid results are blinded.
Several potential limitations of this study should be considered. OSLER included a heterogeneous population who completed phase 2 studies. Although this diversity might be viewed as a strength in terms of the generalizability of the findings, some of the included patients such as the low-risk patients from MENDEL who did not receive statin therapy at baseline may not represent a population that will ultimately receive anti-PCSK9 therapy. Furthermore, it should be noted that 6 dosing regimens of evolocumab were used in the phase 2 parent trials, whereas only the top every-4-weeks dose was used in OSLER. LDL-C measurements were available in 85% of patients at week 52 and imputation was not performed for missing data. However, we do not anticipate that missing data, if observed, would appreciably affect the results or conclusions. OSLER was not designed to rigorously address either the likelihood of LDL-C goal attainment for patients who previously failed to reach lipid goals or to attempt to treat populations to specific targeted levels of LDL-C. Therefore observations made related to these issues should be regarded as exploratory. Finally, the open-label design and more frequent visits for patients allocated to evolocumab limit the interpretation of the relative rates of AEs between the 2 arms.
OSLER was not powered or designed as an outcomes study; rather, the ongoing Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER; NCT01764633) trial will address this important issue. Nonetheless, it is reassuring that adjudicated cardiovascular clinical events occurred no more frequently in evolocumab-treated patients or in patients who reached low LDL-C levels than in SOC patients treated less aggressively. Although the absence of a safety signal provides support for further development of evolocumab, ongoing trials will ultimately determine the benefits, or lack thereof, derived from treatment to reduce LDL-C levels with PCSK9 inhibitors.
Conclusions
The OSLER trial is the largest and longest efficacy and safety evaluation of an anti-PCSK9 antibody to date. Findings in a diverse patient population during >1000 patient-years of observation suggest a highly effective, consistent, and well-tolerated therapy. Ongoing outcomes trials will further define the clinical utility of evolocumab and other agents in its class as an emerging approach to the treatment of hypercholesterolemia. 
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